©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
World J Gastroenterol. Mar 7, 2026; 32(9): 114544
Published online Mar 7, 2026. doi: 10.3748/wjg.v32.i9.114544
Published online Mar 7, 2026. doi: 10.3748/wjg.v32.i9.114544
Lianhe Xiaozhi ointment ameliorates metabolic dysfunction-associated steatotic liver disease via peroxisome proliferator-activated receptor alpha pathway activation
Li-Juan Nie, Gao-Xiang Wang, Xin-Yi Yang, Jing Sun, Yu-Tian Cao, Yan Lou, Yi-Fan Lu, Jiang-Yi Yu, Xi-Qiao Zhou, Department of Endocrinology, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing 210029, Jiangsu Province, China
Li-Juan Nie, Department of Science and Education, Affiliated Psychological Hospital of Anhui Medical University, Hefei Fourth People’s Hospital, Hefei 230022, Anhui Province, China
Xin-Yi Yang, Jing Sun, Yu-Tian Cao, The First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing 210023, Jiangsu Province, China
Co-first authors: Li-Juan Nie and Gao-Xiang Wang.
Author contributions: Zhou XQ and Nie LJ conceived the idea and designed the study; Nie LJ, Wang GX, Yang XY and Zhou XQ wrote the study protocol; Nie LJ, Wang GX, Yang XY, Sun J, Cao YT, Lou Y, Lu YF, Yu JY and Zhou XQ participated in the discussion and modification of the experimental plan; Nie LJ, Wang GX, and Yang XY performed the research and data analyses; Nie LJ wrote the manuscript; Zhou XQ revised the manuscript; all authors had approved the final manuscript for submission.
Supported by the National Natural Science Foundation of China, No. 82474318; the Jiangsu Administration of Traditional Chinese Medicine, No. QN202411; and the Special Fund for Training Outstanding Young Doctors in the Second Session of Jiangsu Province Hospital of Chinese Medicine, No. 2024QB002.
Institutional review board statement: The study does not involve any human experiments.
Institutional animal care and use committee statement: All procedures involving animals were reviewed and approved by the Institutional Animal Care and Use Committee of of Nanjing University of Chinese Medicine (No. 202212A024).
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Data sharing statement: Detailed methods and datasets that support the findings of the present study are available from the corresponding author upon reasonable request.
Corresponding author: Xi-Qiao Zhou, PhD, Professor, Department of Endocrinology, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, No. 155 Hanzhong Road, Qinhuai District, Nanjing 210029, Jiangsu Province, China. zhouxiqiao@njucm.edu.cn
Received: September 30, 2025
Revised: November 6, 2025
Accepted: December 25, 2025
Published online: March 7, 2026
Processing time: 151 Days and 5.3 Hours
Revised: November 6, 2025
Accepted: December 25, 2025
Published online: March 7, 2026
Processing time: 151 Days and 5.3 Hours
Core Tip
Core Tip: Lianhe Xiaozhi ointment effectively alleviates metabolic dysfunction-associated steatotic liver disease by im